Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
Date:12/28/2007

DETROIT, Dec. 28 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD) announced today that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Cetirizine Hydrochloride Tablets, "over the counter", (OTC), 5 mg and 10 mg, (Cetirizine HCl).

Cetirizine HCl, which will be marketed as two separate OTC products in two strengths of 5 mg and 10 mg, is an antihistamine drug, which is used to treat allergies, hives, and other allergic inflammatory conditions. These new products are the bioequivalent to Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R), registered trademarks of Pfizer, Inc.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are pleased to have the opportunity to market these products as they represent the first "over-the counter" products to be added to our current portfolio of prescription products. Zyrtec Allergy(R) has just been approved for the OTC market and we are pleased to be able to market a generic OTC version as an alternative. It previously was marketed strictly as a prescription product under the Zyrtec(R) brand name where it had done over $1.3 billion in prescription sales. We continue to focus on working towards expanding our product offering as quickly and effectively as possible. We plan to market these products to the generic pharmaceutical and OTC market immediately. This will bring our total product selection to 45 different products represented by 96 various strengths."

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward- looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
9. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... ... it is so critically important that we all are aware of our options ... Mediaplanet is proud to announce the launch of its newest edition of "Vision ...
(Date:2/24/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has published ... makes an astounding statement when he says that the entire Bible was written for ... current times so plainly that anyone should be able to see the time period. ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to ... Elite division on February 12th. Ms. Esparza qualified into this prestigious status ... competition held in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to the La Gorce Country Club in Miami Beach to host its Swirl: ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ... santé diversifiée innovante, est ravie d,annoncer les excellents résultats ... la période précédente correspondante. Une présentation complète « Résultats et ... être consultée ici . Faits ... de 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de ...
(Date:2/24/2017)... 2017 Medivir AB (Nasdaq Stockholm: ... new Board of Directors that will be submitted to ... comprises representatives of the company,s three largest shareholders at ... have accepted a seat on the Nomination Committee, and ... 2016-2017 Nomination Committee was as follows:  ...
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017  Genesis ... HME Company. The announcement was made by Bill ... David Hartley and Nathan Feltman , ... of Genesis Healthcare Services, LLC. This ... nation,s largest provider of technology enabled durable medical equipment ...
Breaking Medicine Technology: